MedTrace Logo

BrUOG-PA-209: Lapatinib and Gemcitabine for Metastatic Pancreaticobiliary Cancer

NCT00447122 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2022-03-08

Study results available
· View outcomes & findings →

Summary

Phase I study of lapatinib and gemcitabine for patients with metastatic pancreaticobiliary cancer.

Conditions

Interventions

DRUG

Gemcitabine 1000mg/m2 30 minutes

1000mg/m2 30 minutes

DRUG

Lapatinib 1000mg/d

1000mg/d

DRUG

Lapatinib 1500mg/d

1500mg/d

DRUG

Gemcitabine 1000mg/m2 100minutes

1000mg/m2 100minutes

DRUG

Oxaliplatin 100mg/m2

100mg/m2

Sponsors & Collaborators

  • Rhode Island Hospital

    collaborator OTHER

  • The Miriam Hospital

    collaborator OTHER

  • Memorial Hospital of Rhode Island

    collaborator OTHER

  • Brown University

    lead OTHER

Principal Investigators

  • Howard Safran, MD · Brown University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-03-31
Primary Completion
2008-08-31
Completion
2008-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00447122 on ClinicalTrials.gov